Coexisting Cardiometabolic Conditions and Hypercortisolism

Author(s):

Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE,Ralph DeFronzo, MD

Medical experts discuss the implications of finding hypercortisolism in one-third of patients on three or more hypertension medications, the linkage between hypercortisolism and type 2 diabetes as presented in the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ session, and how hypercortisolism affects diabetes management, including the importance of addressing it and its consequences for patients with difficult-to-control diabetes.

EP: 1.Overview of the CATALYST Study for Hypercortisolism

EP: 2.Defining Difficult to Control Diabetes

EP: 3.CATALYST Trial Study Design

EP: 4.True Prevalence of Hypercortisolism

Now Viewing

EP: 5.Coexisting Cardiometabolic Conditions and Hypercortisolism

EP: 6.Engaging Primary Care Clinicians in Screening for Hypercortisolism

EP: 7.Spectrum of Hypercortisolism Presentations

EP: 8.Mifeprestone for Treatment of Hypercortisolism

EP: 9.Reconsidering Standard of Care for Hypercortisolism

Video content above is prompted by the following:

How do you interpret the finding that one-third of patients on three or more hypertension medications also had hypercortisolism?

You presented the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ at the last ADA scientific session. Can you briefly explain the linkage between hypercortisolism and diabetes?
How does hypercortisolism physiologically impact the management of T2D?
Why is it important to address hypercortisolism? What are the consequences of untreated hypercortisolism in patients with diabetes?
What are the clinical implications of this data? How does it inform or change the way we manage patients with difficult-to-control diabetes?